Liquid Biopsy in Type 2 Diabetes Mellitus Management: Building Specific Biosignatures via Machine Learning
- Supplementary File 1:
ZIP-Document (ZIP, 493 KiB)
Karaglani, M.; Panagopoulou, M.; Cheimonidi, C.; Tsamardinos, I.; Maltezos, E.; Papanas, N.; Papazoglou, D.; Mastorakos, G.; Chatzaki, E. Liquid Biopsy in Type 2 Diabetes Mellitus Management: Building Specific Biosignatures via Machine Learning. J. Clin. Med. 2022, 11, 1045. https://doi.org/10.3390/jcm11041045
Karaglani M, Panagopoulou M, Cheimonidi C, Tsamardinos I, Maltezos E, Papanas N, Papazoglou D, Mastorakos G, Chatzaki E. Liquid Biopsy in Type 2 Diabetes Mellitus Management: Building Specific Biosignatures via Machine Learning. Journal of Clinical Medicine. 2022; 11(4):1045. https://doi.org/10.3390/jcm11041045
Chicago/Turabian StyleKaraglani, Makrina, Maria Panagopoulou, Christina Cheimonidi, Ioannis Tsamardinos, Efstratios Maltezos, Nikolaos Papanas, Dimitrios Papazoglou, George Mastorakos, and Ekaterini Chatzaki. 2022. "Liquid Biopsy in Type 2 Diabetes Mellitus Management: Building Specific Biosignatures via Machine Learning" Journal of Clinical Medicine 11, no. 4: 1045. https://doi.org/10.3390/jcm11041045